Mallinckrodt presents clinical data for terlivaz® (terlipressin) for injection in adults with hepatorenal syndrome (hrs) at digestive disease week (ddw) 2023

– findings from two clinical study presentations in adults with hrs involving rapid reduction in kidney function1 provide insight into the appropriate use of terlipressin for the care of critically ill patients2,3 – dublin , may 8, 2023 /prnewswire/ --  mallinckrodt plc (nyse american: mnk), a global specialty pharmaceutical company, today announced the presentation of results from two clinical studies for adults with hepatorenal syndrome (hrs) with rapid reduction in kidney function1 treated with terlivaz® (terlipressin) for injection at digestive disease week® (ddw) 2023, taking place in chicago, ill. from may 6-9.
MNK Ratings Summary
MNK Quant Ranking